Development of Proteinuria or Elevated Serum Creatinine and Mortality in HIV-Infected Women

BackgroundData on the incidence and prognostic significance of renal dysfunction in HIV disease are limited. ObjectiveTo determine the incidence of proteinuria and elevated serum creatinine in HIV-positive and HIV-negative women and to determine whether these abnormalities are predictors of mortality or associated with causes of death listed on the death certificate in HIV-positive women. DesignThe incidence of proteinuria or elevated serum creatinine and mortality was assessed in a cohort of 885 HIV-positive women and 425 at-risk HIV-negative women. SettingWomen from the general community or HIV care clinics in four urban locations in the United States. Outcome MeasuresCreatinine of ≥1.4 mg/dL, proteinuria 2+ or more, or both. Deaths confirmed by a death certificate (92%) or medical record/community report (8%). ResultsAt baseline, 64 (7.2%) HIV-positive women and 10 (2.4%) HIV-negative women had proteinuria or elevated creatinine. An additional 128 (14%) HIV-positive women and 18 (4%) HIV-negative women developed these abnormalities over the next (mean) 21 months. Relative hazards of mortality were significantly increased (adjusted relative hazard = 2.5; 95% confidence interval: 1.9–3.3), and there were more renal causes recorded on death certificates (24/92 (26%) vs. 3/127 (2.7%), p < .0001) in HIV-infected women with, compared with those without these renal abnormalities. ConclusionsProteinuria, elevated serum creatinine, or both frequently occurred in these HIV-infected women. These renal abnormalities in HIV-infected women are associated with an increased risk of death after controlling for other risk factors and with an increased likelihood of having renal causes listed on the death certificate. The recognition and management of proteinuria and elevated serum creatinine should be a priority for HIV-infected persons.

[1]  J. Flack Effect of ramipril versus amlodipine on renal outcomes in hypertensive nephrosclerosis. , 2002, Current hypertension reports.

[2]  L. Szczech,et al.  Renal diseases associated with human immunodeficiency virus infection: epidemiology, clinical course, and management. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  Keith C. Norris,et al.  Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. , 2001, JAMA.

[4]  J. Rich,et al.  Multicenter evaluation of hepatitis C RNA levels among female injection drug users. , 2001, The Journal of infectious diseases.

[5]  Claude Carbón,et al.  Dramatic improvement of renal dysfunction in a human immunodeficiency virus-infected woman treated with highly active antiretroviral therapy. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  P. Klotman,et al.  HIV-associated nephropathy is a late, not early, manifestation of HIV-1 infection. , 1999, Kidney international.

[7]  J. Papadimitriou,et al.  HIV-1-associated nephropathy and response to highly-active antiretroviral therapy , 1998, The Lancet.

[8]  P. Klotman,et al.  The human immunodeficiency virus (HIV) epidemic and HIV-associated nephropathy. , 1998, Seminars in nephrology.

[9]  D. Vlahov,et al.  Design and baseline participant characteristics of the Human Immunodeficiency Virus Epidemiology Research (HER) Study: a prospective cohort study of human immunodeficiency virus infection in US women. , 1997, American journal of epidemiology.

[10]  S. Sivak,et al.  Effect of angiotensin-converting enzyme inhibition in HIV-associated nephropathy. , 1997, Journal of the American Society of Nephrology : JASN.

[11]  D. Goldfarb,et al.  Immune complex glomerulonephritis in patients coinfected with human immunodeficiency virus and hepatitis C virus. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[12]  F. Locatelli,et al.  Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency , 1996 .

[13]  M. Stampfer,et al.  Test of the National Death Index and Equifax Nationwide Death Search. , 1994, American journal of epidemiology.

[14]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.

[15]  P. Kimmel,et al.  Continuous ambulatory peritoneal dialysis and survival of HIV infected patients with end-stage renal disease. , 1993, Kidney international.

[16]  S. Björck Renal protective effect of enalapril in diabetic nephropathy: Author's reply , 1992, BMJ.

[17]  H. Mulec,et al.  Renal protective effect of enalapril in diabetic nephropathy. , 1992 .

[18]  J. Bourgoignie,et al.  Renal complications of human immunodeficiency virus type 1. , 1990, Kidney international.

[19]  J. Margolick,et al.  Quality control in the flow cytometric measurement of T-lymphocyte subsets: the multicenter AIDS cohort study experience. The Multicenter AIDS Cohort Study Group. , 1990, Clinical immunology and immunopathology.

[20]  J. Bourgoignie,et al.  Outcome of patients with human immunodeficiency virus on maintenance hemodialysis. , 1988, Kidney international.

[21]  S. Edlavitch,et al.  Comparability of mortality follow-up before and after the National Death Index. , 1988, American journal of epidemiology.

[22]  M. Fischl,et al.  Glomerular lesions in the acquired immunodeficiency syndrome. , 1984, Annals of internal medicine.

[23]  E A Friedman,et al.  Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. , 1984, The New England journal of medicine.

[24]  M. H. Gault,et al.  Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.

[25]  R. Marlink,et al.  Clinical care issues for women living with HIV and AIDS in the United States. , 2001, AIDS research and human retroviruses.

[26]  J. Mattana,et al.  Predictors of survival in HIV-infected patients on hemodialysis. , 1996, American journal of nephrology.

[27]  A Fournier,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1994, The New England journal of medicine.

[28]  P. Kimmel,et al.  Effect of race on expression of acquired immunodeficiency syndrome-associated nephropathy. , 1991, Archives of internal medicine.

[29]  D.,et al.  Regression Models and Life-Tables , 2022 .